The FDA in 2017 ripped Indian drugmaker Lupin in a warning letter for not learning from past mistakes. In a new visit to one of the two plants cited in that letter, the FDA has again found issues.
Add Yahoo as a preferred source to see more of our stories on Google. MUMBAI (Reuters) - The U.S. Food and Drug Administration (FDA) has raised concerns over production processes at a plant that makes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results